IP Library Granted Patent US 10,543,187
Granted Patent B2
US 10,543,187 · App. 16/139,937 · Granted Jan 28, 2020

Compositions and methods for stimulating ventilatory and/or respiratory drive

Inventors: Benjamin Gaston (Cleveland, OH); Stephen Lewis (Cleveland, OH)
Assignee: CASE WESTERN RESERVE UNIVERSITY
A61K31/225A61K9/0019A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,187
App. No.
16/139,937
Granted
Jan 28, 2020
Kind
B2
Abstract

A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof.

Claims (22)

1. A pharmaceutical composition comprising:

a respiratory depressant and an amount of a cystine ester or a pharmaceutically acceptable salt thereof effective to restore ventilatory and/or respiratory drive depressed by the respiratory depressant in a subject; wherein the cystine ester has the formula:

where R 1 and R 2 are the same or different and are selected from the group consisting of H, unsubstituted or substituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, heteroaryl, and heterocyclyl containing from 5-14 ring atoms, wherein at least one of R 1 or R 2 is not a H; or pharmaceutically acceptable salts thereof.

2. The composition of claim 1 , wherein the respiratory depressant comprises at least one of an anesthetic, a sedative, an anxiolytic agent, alcohol, or a narcotic.

3. The composition of claim 1 , wherein the respiratory depressant comprises a narcotic analgesic.

4. The composition of claim 1 , wherein the respiratory depressant comprises at least one of an opioid, morphine, fentanyl, oxycodone, or buprenorphine.

5. The composition of claim 1 , wherein R 1 and R 2 are independently H or an unsubstituted or substituted C 1 -C 24 alkyl, wherein at least one of R 1 or R 2 is not a H.

6. The composition of claim 1 , wherein R 1 and R 2 are independently selected from the group consisting of H, methyl, ethyl, propyl, and butyl, wherein at least one of R 1 or R 2 is not a H.

7. The composition of claim 1 , wherein the cystine ester is a cystine dialkyl ester.

8. The composition of claim 7 , wherein the cystine dialkyl ester is a D-cystine dialkyl ester or pharmaceutically acceptable salt thereof.

9. The composition of claim 7 , wherein the cystine dialkyl ester is selected from the group consisting of cystine dimethyl ester, cystine diethyl ester, combinations thereof, and pharmaceutically acceptable salts thereof.

10. The composition of claim 7 , wherein the cystine dialkyl ester is D-cystine dimethyl ester.

11. A composition comprising:

a narcotic analgesic and an amount of a cystine ester or a pharmaceutically acceptable salt thereof effective to restore ventilatory and/or respiratory drive depressed by the narcotic analgesic in a subject; wherein the cystine ester has the formula:

where R 1 and R 2 are the same or different and are selected from the group consisting of H, unsubstituted or substituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, heteroaryl, and heterocyclyl containing from 5-14 ring atoms, wherein at least one of R 1 or R 2 is not a H; or pharmaceutically acceptable salts thereof.

12. The composition of claim 11 , wherein the narcotic analgesic comprises at least one of an opioid, morphine, fentanyl, oxycodone, or buprenorphine.

13. The composition of claim 11 , wherein R 1 and R 2 are independently H or an unsubstituted or substituted C 1 -C 24 alkyl, wherein at least one of R 1 or R 2 is not a H.

14. The composition of claim 11 , wherein R 1 and R 2 are independently selected from the group consisting of H, methyl, ethyl, propyl, and butyl, wherein at least one of R 1 or R 2 is not a H.

15. The composition of claim 11 , wherein the cystine ester is a cystine dialkyl ester.

16. The composition of claim 15 , wherein the cystine dialkyl ester is a D-cystine dialkyl ester or pharmaceutically acceptable salt thereof.

17. The composition of claim 15 , wherein the cystine dialkyl ester is selected from the group consisting of cystine dimethyl ester, cystine diethyl ester, combinations thereof, and pharmaceutically acceptable salts thereof.

18. The composition of claim 15 , wherein the cystine dialkyl ester is D-cystine dimethyl ester.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2019
From: GASTON, BENJAMIN; LEWIS, STEPHEN
To: CASE WESTERN UNIVERSITY
Reel/Frame 051290/0485 →
Continuity (3)
Continuation 15543524
Provisional Application 62102902 · Jan 13, 2015
Related Publication 20190231732A1 · Aug 1, 2019